^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 overexpression

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
    Entrez ID:
    2064
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    1d
    HER2-Targeting and TRAIL-Presenting Protein Nanoparticles Induce a Concentration-Dependent Biphasic Response in HER2-Positive Breast Cancer Cells. (PubMed, Biomacromolecules)
    Unexpectedly, dual-ligand AaLS protein nanoparticles (AaLS/TRAIL/A10 and AaLS/TRAIL/2Rb17C) exhibited biphasic cytotoxicity; low doses synergistically enhanced apoptosis in HER2-positive cells, whereas higher doses reduced efficacy, likely due to the activation of survival signaling. These results highlight the importance of dose optimization for maximizing the use of TRAIL-based targeted therapies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression • HER-2 positive + HER-2 overexpression
    2d
    MCC-20899: Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases (clinicaltrials.gov)
    P1/2, N=31, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 overexpression • HER-2 negative
    |
    Verzenio (abemaciclib) • fulvestrant
    3d
    MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov)
    P3, N=463, Active, not recruiting, Eli Lilly and Company | Trial completion date: Jan 2027 --> Mar 2028
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 overexpression • HER-2 negative
    |
    Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole
    4d
    Genetically encoded self-assembling affibody-streptavidin nanoparticles for HER2-positive cancer theranostics. (PubMed, J Control Release)
    These findings establish avisomes as a highly promising theranostic platform for HER2-positive breast cancer. Its genetically encoded, self-assembling nature eliminates the major limitations of ADCs and synthetic nanoparticles, providing a scalable, reproducible, and cost-efficient alternative for next-generation targeted cancer therapy.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression • HER-2 positive + HER-2 overexpression
    5d
    ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer. (PubMed, World J Surg Oncol)
    The ERBB2 I655V mutation may be associated with improved treatment response to immunotherapy in gallbladder cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TYK2 (Tyrosine Kinase 2)
    |
    PD-L1 expression • HER-2 overexpression • HER-2 mutation
    |
    Focus V (anlotinib) • AiRuiKa (camrelizumab)
    5d
    CD24 overexpression confers resistance to Pyrotinib through inhibiting autophagy in patients with HER2-positive breast cancer. (PubMed, Int J Biol Macromol)
    Furthermore, CD24 knockdown reduced its expression level by promoting the ubiquitination modification of epidermal growth factor receptor (EGFR), and significantly inhibited its downstream AKT/mTOR signaling pathway. By interacting with EGFR and modulating the mTOR pathway, CD24 acted as a critical regulator of autophagic cell death, thereby enhancing the sensitivity of HER2+ BC cells and reversing Pyrotinib resistance.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD24 (CD24 Molecule)
    |
    HER-2 positive • HER-2 overexpression • EGFR positive
    |
    Irene (pyrotinib)
    7d
    HER2-dependent paraptosis and ferroptosis induction by cannabidiol in breast cancer cells. (PubMed, Biochim Biophys Acta Mol Basis Dis)
    These findings support a model in which CBD downregulates HER2 and, in a HER2-dependent context, promotes paraptosis and ferroptosis. In addition, docking and molecular dynamics analyses suggested a potential interaction between CBD and HER2, providing mechanistic insights into possible molecular recognition relevant to HER2-positive breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • ATF4 (Activating Transcription Factor 4)
    |
    HER-2 positive • HER-2 overexpression • HER-2 negative • HER-2 positive + HER-2 overexpression
    8d
    A Study of Tucatinib and Trastuzumab in People With Rectal Cancer (clinicaltrials.gov)
    P2, N=37, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase)
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • RAS wild-type • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type
    |
    Herceptin (trastuzumab) • Tukysa (tucatinib)
    8d
    Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation
    |
    Perjeta (pertuzumab) • trastuzumab rezetecan (SHR-A1811)
    9d
    A single-center, single-arm, exploratory clinical trial investigating the tolerance, safety, and efficacy of xg0201 for her2-positive breast cancer with brain metastases (ChiCTR2500105266)
    P=N/A, N=3, Suspended, The Third Affiliated Hospital of Zhengzhou University; The Third Affiliated Hospital of Zhengzhou University | Recruiting --> Suspended
    Trial suspension
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 positive + HER-2 overexpression
    9d
    A study on the treatment of advanced gastric/gastroesophageal junction adenocarcinoma with docetaxel for injection (albumin-bound type) combined with oxaliplatin and 5-FU/LV (ADOF) (ChiCTR2500112147)
    P=N/A, N=12, Not yet recruiting, Fujian Cancer Hospital; CSPC Zhongqi Pharmaceutical Technology Co., Ltd.
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR • HER-2 overexpression
    |
    5-fluorouracil • oxaliplatin • albumin-bound docetaxel (CPO100)
    9d
    Safety Study of the Combination Regimen Based on HuA21 Monoclonal Antibody for the Treatment of Advanced HER2-overexpressing Solid Tumors (ChiCTR2500112039)
    P=N/A, N=90, Not yet recruiting, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Herceptin (trastuzumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel